BiotechTube
Adecto Pharmaceuticals

Adecto Pharmaceuticals

Cambridge, United States· Est.
adectopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Adecto Pharmaceuticals is a private, pre-clinical stage biotherapeutic company targeting ADAM8-positive cancers, including colorectal, breast, and kidney cancers, with a novel monoclonal antibody. Its technology is designed to overcome limitations of current immunotherapies by reprogramming both lymphoid and myeloid immune cells, not just T-cells. Founded by seasoned researchers, the company is led by CEO & CSO Dr. Nora Mineva and is focused on advancing its lead candidate through preclinical development. Adecto is currently pre-revenue and is engaged in fundraising and corporate development activities.

Oncology

Technology Platform

Monoclonal antibody platform targeting ADAM8 to reprogram both lymphoid and myeloid immune cells in the tumor microenvironment, overcoming resistance to conventional T-cell-focused immunotherapies.

Opportunities

Targets a large unmet need in oncology: patients with aggressive solid tumors resistant to current immunotherapies.
The approach of reprogramming myeloid cells could unlock responses in 'cold' tumors, representing a significant expansion of the addressable market for immuno-oncology.
Successful preclinical validation could attract partnership deals with larger pharma companies seeking to enhance their I-O pipelines.

Risk Factors

High preclinical risk that the ADAM8 mechanism will not prove safe or effective in human trials.
Total dependence on raising additional capital in a challenging financing environment for early-stage biotech.
Intense competition in the immuno-oncology space from companies with greater resources pursuing similar myeloid-targeting strategies.

Competitive Landscape

Adecto competes in the crowded immuno-oncology field, where giants like Merck, Bristol-Myers Squibb, and Roche dominate with T-cell checkpoint inhibitors. Its direct competitors are smaller biotechs and academic spin-outs developing therapies to modulate the myeloid compartment (e.g., targeting CD47, CSF1R, CD40) or other novel immune pathways. Differentiation hinges on the unique biology of ADAM8 and its dual impact on lymphoid and myeloid cells.

More companies in Biologics / Biosimilars →More companies in United States →